Kindblom LG, Remotti HE, Aldenborg F, et al. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol. 1998;152:1259–69.

CAS  PubMed  PubMed Central  Google Scholar 

Parab TM, DeRogatis MJ, Boaz AM, et al. Gastrointestinal stromal tumors: a comprehensive review. J Gastrointest Oncol. 2019;10:144–54.

Article  PubMed  PubMed Central  Google Scholar 

Hemming ML, Heinrich MC, Bauer S, et al. Translational insights into gastrointestinal stromal tumor and current clinical advances. Ann Oncol. 2018;29:2037–45.

Article  CAS  PubMed  Google Scholar 

Boikos SA, Pappo AS, Killian JK, et al. Molecular subtypes of KIT/PDGFRA wild-type gastrointestinal stromal tumors: a report from the national institutes of health gastrointestinal stromal tumor clinic. JAMA Oncol. 2016;2:922–8.

Article  PubMed  PubMed Central  Google Scholar 

Andersson J, Sihto H, Meis-Kindblom JM, et al. NF1-associated gastrointestinal stromal tumors have unique clinical, phenotypic, and genotypic characteristics. Am J Surg Pathol. 2005;29:1170–6.

Article  PubMed  Google Scholar 

Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med. 2001;344:1052–6.

Article  CAS  PubMed  Google Scholar 

Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368:1329–38.

Article  CAS  PubMed  Google Scholar 

Demetri GD, Reichardt P, Kang YK, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381:295–302.

Article  CAS  PubMed  Google Scholar 

Janku F, Abdul Razak AR, Chi P, et al. Switch control inhibition of KIT and PDGFRA in patients with advanced gastrointestinal stromal tumor: a phase i study of ripretinib. J Clin Oncol. 2020;38:3294–303.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ray K. Ripretinib for advanced gastrointestinal stromal tumours. Nat Rev Gastroenterol Hepatol. 2020;17:452.

PubMed  Google Scholar 

Reck M, Remon J, Hellmann MD. First-line immunotherapy for non-small-cell lung cancer. J Clin Oncol. 2022;40:586–97.

Article  CAS  PubMed  Google Scholar 

Sangro B, Sarobe P, Hervas-Stubbs S, et al. Advances in immunotherapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021;18:525–43.

Article  PubMed  PubMed Central  Google Scholar 

Thoma C. Kidney cancer: combining targeted and immunotherapy. Nat Rev Urol. 2018;15:263.

PubMed  Google Scholar 

Finck AV, Blanchard T, Roselle CP, et al. Engineered cellular immunotherapies in cancer and beyond. Nat Med. 2022;28:678–89.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Adusumilli PS, Zauderer MG, Riviere I, et al. A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab. Cancer Discov. 2021;11:2748–63.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sun X, Shu P, Fang Y, et al. Clinical and prognostic significance of tumor-infiltrating CD8+ T cells and PD-L1 expression in primary gastrointestinal stromal tumors. Front Oncol. 2021;11: 789915.

Article  PubMed  PubMed Central  Google Scholar 

Sun X, Sun J, Yuan W, et al. Immune cell infiltration and the expression of PD-1 and PD-L1 in primary PDGFRA-mutant gastrointestinal stromal tumors. J Gastrointest Surg. 2020. https://doi.org/10.1007/s11605-020-04860-8.

Article  PubMed  Google Scholar 

van Dongen M, Savage ND, Jordanova ES, et al. Anti-inflammatory M2 type macrophages characterize metastasized and tyrosine kinase inhibitor-treated gastrointestinal stromal tumors. Int J Cancer. 2010;127(4):899–909.

PubMed  Google Scholar 

Cameron S, Gieselmann M, Blaschke M, et al. Immune cells in primary and metastatic gastrointestinal stromal tumors (GIST). Int J Clin Exp Pathol. 2014;7:3563–79.

CAS  PubMed  PubMed Central  Google Scholar 

Rusakiewicz S, Semeraro M, Sarabi M, et al. Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors. Can Res. 2013;73:3499–510.

Article  CAS  Google Scholar 

Balachandran VP, Cavnar MJ, Zeng S, et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med. 2011;17:1094–100.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen LL, Chen X, Choi H, et al. Exploiting antitumor immunity to overcome relapse and improve remission duration. Cancer Immunol Immunother. 2012;61:1113–24.

Article  CAS  PubMed  Google Scholar 

Sun C, Mezzadra R, Schumacher TN. Regulation and function of the PD-L1 checkpoint. Immunity. 2018;48:434–52.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Feng M, Jiang W, Kim BYS, et al. Phagocytosis checkpoints as new targets for cancer immunotherapy. Nat Rev Cancer. 2019;19:568–86.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Newman AM, Liu CL, Green MR, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12:453–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Joensuu H, Vehtari A, Riihimaki J, et al. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol. 2012;13:265–74.

Article  PubMed  Google Scholar 

El-Menyar A, Mekkodathil A, Al-Thani H. Diagnosis and management of gastrointestinal stromal tumors: an up-to-date literature review. J Cancer Res Ther. 2017;13:889–900.

CAS  PubMed  Google Scholar 

Burch J, Ahmad I. Gastrointestinal stromal cancer. Treasure Island: StatPearls; 2022.

Google Scholar 

Lu X. OX40 and OX40L interaction in cancer. Curr Med Chem. 2021;28:5659–73.

Article  CAS  PubMed  Google Scholar 

Deng J, Zhao S, Zhang X, et al. OX40 (CD134) and OX40 ligand, important immune checkpoints in cancer. Onco Targets Ther. 2019;12:7347–53.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim MY, Gaspal FM, Wiggett HE, et al. CD4(+)CD3(-) accessory cells costimulate primed CD4 T cells through OX40 and CD30 at sites where T cells collaborate with B cells. Immunity. 2003;18:643–54.

Article  CAS  PubMed  Google Scholar 

Gracias DT, Sethi GS, Mehta AK, et al. Combination blockade of OX40L and CD30L inhibits allergen-driven memory TH2 cell reactivity and lung inflammation. J Allergy Clin Immunol. 2021;147:2316–29.

Article  CAS  PubMed  Google Scholar 

Zhang X, Xiao X, Lan P, et al. OX40 costimulation inhibits Foxp3 expression and treg induction via BATF3-dependent and independent mechanisms. Cell Rep. 2018;24:607–18.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Piconese S, Valzasina B, Colombo MP. OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection. J Exp Med. 2008;205:825–39.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Voo KS, Bover L, Harline ML, et al. Antibodies targeting human OX40 expand effector T cells and block inducible and natural regulatory T cell function. J Immunol. 2013;191:3641–50.

Article  CAS  PubMed  Google Scholar 

Ye K, Li F, Wang R, et al. An armed oncolytic virus enhances the efficacy of tumor-infiltrating lymphocyte therapy by converting tumors to artificial antigen-presenting cells in situ. Mol Ther. 2022. https://doi.org/10.1016/j.ymthe.2022.06.010.

Article  PubMed  PubMed Central  Google Scholar 

Song M, Gao J, Yan T, et al. Hsa_circ_0000652 aggravates inflammation by activation of macrophages and enhancement of OX40/OX40L interaction in ankylosing spondylitis. Front Cell Dev Biol. 2021;9: 737599.

Article  PubMed  PubMed Central  Google Scholar